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Safety was characterized by ADR reporting and discontinuation
of treatment. Medication effectiveness was determined by per-
sistence on the subsequent alternative alpha1-antagonist.
RESULTS: Of 226 patient requests submitted, 55 (24.3%) were
denied. Patients averaged 17.9 months (±12.4) on tamsulosin
prior to denial. After 90-days, 67.3% remained on the recom-
mended alternative alpha1-antagonist, 14.5% had no alternative
ordered and no tamsulosin dispensed, 9.1% remained on 
tamsulosin from VASDHS, 5.5% continued tamsulosin from
non-VASDHS sources, 3.6% required changing to a second 
non-tamsulosin alternative, and adverse events occurred in
9.1%. The cost of a prescriber entering a reauthorization request
was $8.19/patient while adjudication by a pharmacist was
$11.61/patient. Few telephone contacts(10), unscheduled clinic
visits(1), and urgent care visits(0) occurred adding $5.29 per
patient per month (PPPM). Prescription costs were $9.82 PPPM
for patients denied versus an estimated $43.87 for those
approved. The total cost of 226 requests, excluding scheduled
clinic visits, was $128.94/patient versus an estimated
$131.58/patient if the program had not been implemented.
CONCLUSION: Overall outcomes and associated costs incurred
in a tamsulosin reauthorization program eliminated much of the
anticipated cost savings in the 90-days following a denial.
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OBJECTIVE: Early care provided by nephrologists before ini-
tiating dialysis may improve treatment outcomes for patients
who later progress to end-stage renal disease (ESRD) and start
hemodialysis. The objective is to identify factors inﬂuencing early
nephrology care, deﬁned as visiting a nephrologist from 4 to 12
months prior to hemodialysis initiation among elderly ESRD
patients. METHODS: The study population consists of patients
initiating hemodialysis in the years 1996–1999, aged 67+ years
and having Medicare Part B coverage in the fee-for-service
system in the 2nd year prior to dialysis initiation. Patients’ char-
acteristics were obtained from Centers for Medicare & Medic-
aid Services form 2728 ﬁles. Comorbidities and hospital
utilization were generated from Medicare Part A and/or Part B
claims. Physician visits including early nephrology care and
access to non-nephrologist physicians and nephrologists practic-
ing in a local area, deﬁned as an area 30 miles within a patient’s
residence ZIP code, were computed with Medicare Part B physi-
cian/supplier ﬁles and US 2000 Census data. RESULTS: About
33.79% of 91,189 elderly patients received early nephrology
care before starting hemodialysis. Logistic regressions indicated
that patients who were male, had hypertension, anemia, more
hospital admissions in the year before initiating dialysis, lived in
an area with more nephrologists per 1000 prevalent elderly
ESRD patients were more likely to obtain early nephrology care.
Patients older than 76 years, having diabetes, living in an area
with more non-nephrologist physicians per 10,000 population
had a lower likelihood of getting early nephrology care. Patients
residing in areas 12 miles or more away from the nearest
nephrologist had a smaller odds ratio of receiving early nephrol-
ogy care compared to patients living in an area less than 4 miles
away. CONCLUSIONS: Elderly ESRD patients’ characteristics
and access to local non-nephrologist physicians and nephrolo-
gists affect the use of early nephrology care prior to hemodialy-
sis initiation.
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OBJECTIVES: Zero-mass cost values, heteroskedasticity and re-
transformation are three common problems in health care expen-
diture models. In this paper, we applied recently proposed
methodology which deals with these three common problems
simultaneously. METHODS: Two parts models are suitable for
estimating right-skewed cost data. The main complication in this
case is the retransformation where smearing estimation fails
when there is evidence of heteroskedasticity which is very
common in analyzing health care expenditures. Recently pro-
posed “internal” and “external” estimators remove the bias in
log-transformed two part model with heteroskedasticity. First,
we estimate probability of having zero cost by logit (h), and then
create internal weight which is equal to (1-h)/(1-m) where m is
the average of the estimated probabilities and external weight
which is equal to (1-h). The retransformed cost for the non-zero
cost sample is multiplied by internal weight to get internal trans-
formed cost. External transformed cost can be calculated by
averaging external weighted cost over the no-zero cost sample.
RESULTS: The method is applied to Market Scan Data which
based upon patients with chronic kidney disease. Total inpatient
cost is estimated using log transformed two part model. Fifty-six
percent of the patient sample had zero cost. White Test proved
heteroskedasticity. Internal and External estimators yield similar
results (p = 0.852) but they were statistically different from 
the standard estimator which ignores heteroskedasticity in 
re-transformation (p = 0.000). CONCLUSIONS: Re-
transformation bias in two part models can be eliminated using
internal and external weighted estimators.
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OBJECTIVES: Health outcome measurement in patients with
Overactive Bladder (OAB) is largely based on condition speciﬁc
measures such as the OAB-q and King’s Health Questionnaire
(KHQ). Generic preference-based measures of health (e.g. SF-36
and EQ-5D) have not shown to be sensitive in OAB patients.
The condition speciﬁc measures are not preference based; a
requirement for QALY estimation. To date, cost-effectiveness
studies of treatments for OAB have relied upon treatment per-
sistency as a proxy for health outcome. However, recent research
has shown it is possible to estimate a preference-based single
index using the KHQ. The purpose of this study was to test the
application of such an index by estimating and comparing
changes in quality adjusted life years (QALYs) in a population
of OAB patients either receiving pharmacologic treatment for
OAB or not. METHODS: Patients’ KHQ scores were trans-
formed into a 5 dimensional health state classiﬁcation amenable
to valuation (role limitation, physical limitation, social limita-
tion, emotions and sleep). Patient level data, including KHQ
scores were taken from a sample of patients with OAB in the UK
and Germany. The modelled beta coefﬁcients associated with
each level of each dimension was applied to the health state clas-
siﬁcations. Changes in utility were then estimated by measuring
the difference between results at 2 different time points, baseline,
and 12 weeks after treatment. RESULTS: Data from 175 patients
